Drug intelligence / Profile preview

SKP-1052

Development stage: Unknown
Lead developer: SkyePharma
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

SKP-1052 is a modified-release oral formulation of terbutaline developed to prevent hypoglycemia, particularly in individuals with diabetes. Unlike immediate-release terbutaline (IRT), SKP-1052 delays the release of terbutaline, resulting in a more gradual increase in blood glucose levels over several hours post-dose without causing fasting hyperglycemia. This pharmacokinetic profile aims to provide sustained protection against nocturnal or delayed-onset hypoglycemia by maintaining higher blood glucose levels during vulnerable periods[1][2].

Other names: modified release terbutaline

Targets

ADRB2 (β2)

Beyond the preview

Go deeper on SKP-1052.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SKP-1052.

Explore the full profile